Replies to post #211551 on Biotech Values

[DFRAI]

TRIL financing

How do you figure that recent financing is counter to all bulish bias about CD47/TRIL?

In retrospect they made a huge financing mistake last year by not raising 30 million at 15 which would have been a 20% dilution.

Now 7 months later they are forced to dilute greater because of the increased trial expenses.
Why would anyone give them money without vetting the technology/results which typical shareholder does not get to see?

Can you cite any negative CD47 studies that support your theory?